Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review by Kiran Shah, Nirali Shah, Fatameh Ghassemi, Carolyn Ly, Teena George, Carla Lutz, Huseyin Sumer

“…The area has been further strengthened with the approval of Chimeric Antigen Receptor added on T cells (CAR-T) therapies by the regulatory authorities USA’s Food and Drugs Administration (FDA), European Medical Agency (EMA), the Australian Therapeutic Goods Administration (TGA), and in many countries in 2017 to treat hematological cancers. …”
Get full text

Engineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia by Philipp Koehler, Patrick Schmidt, Andreas A. Hombach, Michael Hallek, Hinrich Abken

“…Cytolytic T cells from patients are redirected towards CLL cells by ex vivo engineering with a chimeric antigen receptor (CAR) which binds to CD19 on CLL cells through an antibody-derived domain and triggers T cell activation through CD3ζ upon tumor cell engagement. …”
Get full text

ErbB- and MUC1-targeted CAR-T cell immunotherapy of oral squamous cell carcinoma by Saffron E. Summers, Saffron E. Summers, Vehid Salih, Andrew D. Foey

“…Chimeric antigen receptor T (CAR-T) cell therapy has shown great success in treating B cell malignancies; however, there are many challenges that limit their therapeutic efficacy in solid tumours. …”
Get full text

Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma by Gustavo de Oliveira Canedo, Claire Roddie, Persis J. Amrolia

“…Abstract: Relapse after CD19-directed chimeric antigen receptor (CAR) T-cell therapy remains a major challenge in B-cell acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma (B-NHL). …”
Get full text

Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma by Qing Zhang, Kang Tian, Jinjing Xu, Haixu Zhang, Liantao Li, Qiang Fu, Dafei Chai, Huizhong Li, Junnian Zheng

“…The chimeric antigen receptor-modified immune effector cell (CAR-T and CAR-NK) therapies are newly developed adoptive treatments of cancers. …”
Get full text

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma? by Davor Galusic, Ivan Krecak, Viktor Blaslov, Andela Krstulovic Opara, Toni Valkovic, Sandra Basic Kinda

“…Due to the cost and availability of bispecific T cell redirecting antibodies (BsAbs) and chimeric antigen receptor T cell therapy (CAR-T) in real-life settings in many countries, retreatment with daratumumab in subsequent lines of therapy might be a reasonable choice. …”
Get full text

From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy by E. Pinto, L. Lione, M. Compagnone, M. Paccagnella, E. Salvatori, M. Greco, V. Frezza, E. Marra, L. Aurisicchio, G. Roscilli, A. Conforti

“…Abstract In the past decades, Chimeric Antigen Receptor (CAR)-T cell therapy has achieved remarkable success, leading to the approval of six therapeutic products for haematological malignancies. …”
Get full text

The Efficacy of Chimeric Antigen Therapy in Viral Infectious Diseases: A Systematic Review of Randomized Controlled Trials by Hossein Hatami, Elnaz Ataei, Mohammadjavad Nasiri, Hamed Ghorani

“…It is shown that chimeric antigen receptor (CAR) T-cell therapy can fight viral infectious diseases in many aspects. …”
Get full text

Advancements in cellular immunotherapy: overcoming resistance in lung and colorectal cancer by Lijuan Qin, Yuan Li, Juan Liu, Xiaoqin An

“…Among the most promising approaches are cellular therapies, particularly chimeric antigen receptor T-cell (CAR-T) therapy, which has shown remarkable success in hematologic malignancies. …”
Get full text

Upregulation of CD19 by low‐dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma by Ying Ni, Qun Zhang, Xiaochen Tang, Xiuchun Li, Shiguang Ye, Yan Lu, Aibin Liang, Ping Li

“…In recent years, CD19 Chimeric antigen receptor T (CAR T) cell immunotherapy has significantly improved the cure rate of B-NHL patients, but there are still some patients who cannot achieve remission after treatment, or relapse after remission. …”
Get full text

Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients by Kamel Ait-Tahar, Amanda P. Anderson, Martin Barnardo, Graham P. Collins, Chris S. R. Hatton, Alison H. Banham, Karen Pulford

“…Success using immune checkpoint inhibitors and chimeric antigen receptor T cell technology has fuelled demand for validated cancer epitopes. …”
Get full text

Modified CD15/CD16-CLL1 inhibitory CAR-T cells for mitigating granulocytopenia toxicities in the treatment of acute myeloid leukemia by Rui Zhang, Yifan Zhao, Xiao Chai, Yingshuai Wang, Mohan Zhao, Shujing Guo, Yu Zhang, Mingfeng Zhao

“…CLL1 Chimeric antigen receptor T-cell (CAR-T) therapy, as a promising immunotherapeutic approach, has demonstrated its potential to enhance the prognosis of patients diagnosed with acute myeloid leukemia (AML). …”
Get full text

Molecular Mechanisms and Therapeutic Prospects of Immunotherapy and Targeted Therapy in Primary Central Nervous System Lymphoma by Lin Zhong MM, Anqing Lu MB, Xiyue Lu MM, Xiaoyin Liu MD, Lujia Cao MM, Shihong Zhu MM, SiJun Diao MM, Xu Cheng MM, Hongwei Wu MB, Jing Chen MD

“…With a deeper understanding of the pathophysiology of PCNSL, various therapies, including CD20 monoclonal antibodies, Bruton's tyrosine kinase (BTK) inhibitors, immunomodulatory drugs, immune checkpoint inhibitors, phosphoinositide 3-kinase (PI3 K)/mammalian target of rapamycin(mTOR) inhibitors, and chimeric antigen receptor (CAR) -T cells are increasingly being applied and have demonstrated considerable efficacy. …”
Get full text

Pooled screening for CAR function identifies novel IL-13Rα2-targeted CARs for treatment of glioblastoma by Douglas A Lauffenburger, Khloe S Gordon, Caleb R Perez, Andrea Garmilla, Maxine S Y Lam, Joey J Y Aw, Anisha Datta, Andrea Pavesi, Michael E Birnbaum

“…Background Chimeric antigen receptor (CAR) therapies have demonstrated potent efficacy in treating B-cell malignancies, but have yet to meaningfully translate to solid tumors. …”
Get full text

Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed/refractory diffuse large B-cell lymphoma by Rui Zhang, Yi Zhang, Hairong Xiao, Qingxi Liu, Mingfeng Zhao

“…Abstract Chimeric antigen receptor (CAR) T-cell therapy plays a critical role in the treatment of B-cell hematologic malignancies. …”
Get full text

Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors by Hui Wang, Yi Zhang, Feng Li, Shasha Liu, Shumin Wang, Wenhao Hu, Yue Liang, Chunyi Shen, Yuyu Zhao

“…Furthermore, glucose restriction can contribute to the failure of chimeric antigen receptor T (CAR-T) cell therapy for solid tumors. …”
Get full text

Diabetes insipidus and Guillain-Barré-like syndrome following CAR-T cell therapy: a case report by Christian Koch, Patrick Roth, Juliane Fleischer, Todor Popov, Karl Frontzek, Bettina Schreiner, Markus G. Manz, Simone Unseld, Antonia M. S. Müller, Norman F. Russkamp

“…Background Immune effector cell-associated neurotoxicity syndrome (ICANS) is a common adverse event of CD19-directed chimeric antigen receptor (CAR) T cell therapy. Other neurological adverse events, however, have not methodically been described and studied. …”
Get full text

Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy by Lichen Zhu, Xiaomei Yang, Dani Zhong, Shenxia Xie, Wei Shi, Yangzi Li, Xiaoqiong Hou, HuaYao, Huihui Zhou, Minlong Zhao, Ziqiang Ding, Xinyue Zhao, Fengzhen Mo, Shihua Yin, Aiqun Liu, Xiaoling Lu

“…Retargeting the antigen-binding specificity of T cells to intracellular antigens that are degraded and presented on the tumor surface by engineering chimeric antigen receptor (CAR), also named TCR-like antibody CAR-T, remains limited. …”
Get full text

Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung by Tianchuan Zhu, Yuchen Xiao, Zhenxing Chen, Hanxi Ding, Shoudeng Chen, Guanmin Jiang, Xi Huang

“…Abstract Suppression of chimeric antigen receptor-modified T (CAR-T) cells by the immunosuppressive tumor microenvironment remains a major barrier to their efficacy against solid tumors. …”
Get full text

Exploring Glypican-3 targeted CAR-NK treatment and potential therapy resistance in hepatocellular carcinoma. by Lei Yang, Kien Pham, Yibo Xi, Qunfeng Wu, Dongfang Liu, Keith D Robertson, Chen Liu

“…Therefore, developing novel treatment options for patients with HCC is urgently needed. Chimeric antigen receptor (CAR)-modified natural killer (NK) cells have demonstrated potent anti-tumor effects, making them as a promising immunotherapy strategy for cancer treatment. …”
Get full text